Overview

A Study of LY3541105 in Healthy and Overweight Participants

Status:
Recruiting
Trial end date:
2023-08-04
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight. This is a 2-part study and may last up to 15 and 26 weeks for each participant and may include up to 7 and 15 visits in parts A and B, respectively.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company